Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

A liver ultrasound is a quick, safe, painless, and relatively inexpensive test. However, the definite diagnosis of your condition may require additional testing.

France’s Sanofi – a major player in the rare disease category – is offering $30 per share for La Jolla, California-based Inhibrx, which had a closing price of just over $33 yesterday.

The study is intended to focus on diagnostics and treatment of Lyme IACI symptoms and not to improve diagnostics and treatment for acute Lyme disease. As such, the prevention of Lyme disease ...

There is a paucity of studies looking at the natural history of valvular heart disease (VHD) in exercising individuals, and exercise recommendations are largely based on expert consensus. All ...